Vnitr Lek 2012, 58(6):448-454

An effect of continuous and intermittent renal replacement therapy on antibiotic treatment in critically ill patients with sepsis - a practice-based perspective of vancomycin and gentamycin therapies

N. Petejová1,*, A. Martínek1, J. Zahálková2,3, J. Ďuricová4, J. Plášek1, I. Valkovský1, M. Grundmann4, I. Kacířová4
1 Interní klinika Lékařské fakulty OU a FN Ostrava, přednosta doc. MUDr. Arnošt Martínek, CSc.
2 III. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc.
3 Hemodialyzační oddělení Šternberk, Středomoravská nemocniční a. s., prim. MUDr. Jana Zahálková, Ph.D.
4 Ústav klinické farmakologie Lékařské fakulty OU a FN Ostrava, přednostka MUDr. Ivana Kacířová, Ph.D.

Sepsis and septic shock are common cause of hospitalisation in intensive care unit. Acute kidney injury is an accompanying manifestation of sepsis/septic shock leading to worsening of morbidity and also mortality and requiring use of intermittent or continual renal replacement therapy. Life saving effect is attributed to early and effective antibiotic therapy. Therapeutic drug monitoring and dosage adjustment is important for successful treatment. Despite therapeutic drug monitoring of both antibiotic agents vankomycin and gentamicin the treatment still rises many questions about the convenient use in septic patients due to their nephrotoxicity.

Keywords: acute kidney injury; renal replacement therapy; antibiotic pharmacokinetics

Received: May 3, 2011; Accepted: February 6, 2012; Published: June 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petejová N, Martínek A, Zahálková J, Ďuricová J, Plášek J, Valkovský I, et al.. An effect of continuous and intermittent renal replacement therapy on antibiotic treatment in critically ill patients with sepsis - a practice-based perspective of vancomycin and gentamycin therapies. Vnitr Lek. 2012;58(6):448-454.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rangel-Frausto MS, Pittet D, Costigan M et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273: 117-123. Go to original source...
    2. Bagshaw SM, Uchino S, Bellomo R et al. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007; 2: 431-439. Go to original source... Go to PubMed...
    3. Bellomo R, Ronco C, Kellum JA et al. Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212. Go to original source... Go to PubMed...
    4. Wan L, Bagshaw SM, Langenberg C et al. Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 2008; 36: S198-S203. Go to original source... Go to PubMed...
    5. Lerolle N, Nochy D, Guérot E et al. Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med 2010; 36: 471-478. Go to original source... Go to PubMed...
    6. Rana A, Sathyanarayana P, Lieberthal W. Role of apoptosis of renal tubular cells in acute renal failure: therapeutic implications. Apoptosis 2001; 6: 83-102. Go to original source... Go to PubMed...
    7. Homsi E, Janino P, de Faria JB. Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int 2006; 69: 1385-1392. Go to original source... Go to PubMed...
    8. Bernard GR, Vincent JL, Laterre PF et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709. Go to original source... Go to PubMed...
    9. Dellinger RP, Vincent JL, Marshall J et al. Important issues in the design and reporting of clinical trials in severe sepsis and acute lung injury. J Crit Care 2008; 23: 493-499. Go to original source... Go to PubMed...
    10. Matějovič M. Ledviny v sepsi. Postgraduální medicína 2010; 9: 1042-1047.
    11. Opatrný K jr. Kontinuální mimotělní metody nahrazující funkci ledvin. Vnitř Lék 1996; 12: 818-824.
    12. Bellomo R, Palevsky PM, Bagshaw SM et al. Recent trials in critical care nephrology. Contrib Nephrol 2010; 165: 299-309. Go to original source... Go to PubMed...
    13. Uchino S. What is 'BEST' RRT practice? Contrib Nephrol 2010; 165: 244-250. Go to original source... Go to PubMed...
    14. Choi G, Gomersall CD, Tian Q et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 7: 2268-2282. Go to original source... Go to PubMed...
    15. Kuang D, Verbine AR, Ronco C. Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy. Clinical Nephrol 2007; 67: 267-284. Go to original source... Go to PubMed...
    16. Churchwell MD, Muellert BA. Drug dosing during continuous renal replacement therapy. Semin Dial 2009; 22: 185-188. Go to original source... Go to PubMed...
    17. Veltri MA, Neu AM, Fivush BA et al. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. Paediatr Drugs 2004; 6: 45-65. Go to original source... Go to PubMed...
    18. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006; 22: 255-271. Go to original source... Go to PubMed...
    19. Fülöp T, Pathak MB, Schmidt DW et al. Volume-related weight gain and subsequent mortality in acute renal failure patients treated with continuous renal replacement therapy. ASAIO J 2010; 56: 333-337. Go to original source... Go to PubMed...
    20. Novák I, Matějovič M, Černý V et al. Akutní selhání ledvin a eliminační techniky v intenzivní péči. Praha: Maxdorf 2008: 107-122.
    21. Eyler RF, Mueller BA. Medscape. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol 2011; 7: 226-235. Go to original source... Go to PubMed...
    22. Černý V, Kula R, Novák I et al. Sepse v intenzivní péči. Vybraná doporučení v diagnostice a terapii. Praha: Maxdorf 2005: 49-58.
    23. Burton ME, Shaw LM, Scheritag JJ et al. Applied Pharmacokinetics & Pharmacodynamics Principles of Therapeutic Drug Monitoring. Philadelphia PA: Lippincote Williams & Wilkins 2006: 285-353.
    24. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 2009; 66: 82-98. Go to original source... Go to PubMed...
    25. James JK, Palmer SM, Levine DP et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996; 40: 696-700. Go to original source... Go to PubMed...
    26. Touchette MA, Patel RV, Anandan JV et al. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis 1995; 26: 469-474. Go to original source... Go to PubMed...
    27. Ariano RE, Fine A, Sitar DS et al. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 2005; 46: 681-687. Go to original source... Go to PubMed...
    28. Ahern JW, Lai C, Rebuck JA et al. Experience with Vancomycin in patients receiving slow low-efficiency dialysis. Hosp Pharm 2004; 39: 138-143. Go to original source...
    29. Kielstein JT, Czock D, Schöpke T et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34: 51-56. Go to original source... Go to PubMed...
    30. Pallotta KE, Manley HJ. Vancomycin use in patients requiring hemodialysis: a literature review. Semin Dial 2008; 21: 63-70. Go to original source... Go to PubMed...
    31. Del Dot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004; 58: 259-268. Go to original source... Go to PubMed...
    32. Zahálková J, Strojil J, Petejová N et al. Dávkovaní vankomycinu při kontinuální náhradě funkce ledvin. Klin Farmakol Farm 2011; 25: 116-121.
    33. Halpren BA, Axline SG, Coplon NS et al. Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys. J Infect Dis 1976; 133: 627-636. Go to original source... Go to PubMed...
    34. Gyselynck AM, Forrey A, Cutler R. Pharmacokinetics of gentamicin: distribution and plasma and renal clearance. J Infect Dis 1971; 124 (Suppl): S70-S76. Go to original source... Go to PubMed...
    35. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29: 562-577. Go to original source... Go to PubMed...
    36. Trotman RL, Williamson JC, Shoemaker DM et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41: 1159-1166. Go to original source... Go to PubMed...
    37. Roberts JA, Field J, Visser A et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 2010; 54: 3635-3640. Go to original source... Go to PubMed...
    38. Rea RS, Capitano B, Bies R et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30: 674-681. Go to original source... Go to PubMed...
    39. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993; 21: 172-173. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.